MedicGo
QT interval prolongation related to afatinib treatment in a patient with metastatic non-small-cell lung cancer.
Metadata
Journalcurrent problems in cancer3.264Date
2020 May 27
4 months ago
Type
Case Report
Volume
2020-May-27 / : 100594
Author
Demircan NC 1, Akın Telli T 2, Başoğlu Tüylü T 2, Arıkan R 2, Kocakaya D 3, Şahin AA 4, Ercelep Ö 2, Dane F 2, Yumuk PF 2
Affiliation
  • 2. Marmara University School of Medicine, Department of Internal Medicine, Division of Medical Oncology, Istanbul, Turkey.
  • 3. Marmara University School of Medicine, Department of Pulmonary Medicine, Istanbul, Turkey.
  • 4. Marmara University School of Medicine, Department of Cardiology, Istanbul, Turkey.
Doi
PMIDMESH
Abstract
Afatinib improves survival in metastatic non-small-cell lung cancer driven by activating epidermal growth factor receptor mutations. QT interval prolongation is a possible side effect of targeted anticancer drugs, but this has not been reported before with afatinib. We report a case of metastatic pulmonary adenocarcinoma with epidermal growth factor receptor exon 19 deletion who was treated with first-line afatinib. The patient was started on afatinib with a total dose of 40 mg/day and experienced grade 3 (>500 ms) QT interval prolongation in the seventh week. Dose was interrupted and then reduced to 30 mg/day after the event repeated. QT prolongation occurred only once with the reduced dose and radiologic oligoprogression was detected. Local therapy was performed and afatinib was continued as 30 mg/day. To the best of our knowledge, this case marks the first QT interval prolongation associated with afatinib. It is prudent to perform a baseline cardiologic evaluation and electrocardiogram monitoring in non-small cell lung cancer patients treated with this drug.
Keywords: Afatinib Epidermal growth factor receptor Non–small-cell lung cancer QT prolongation Tyrosine kinase inhibitor
Fav
Like
Download
Share
Export
Cite
3.3
Curr Probl Cancercurrent problems in cancer
Metadata
LocationUnited States
FromMOSBY-ELSEVIER

No Data

© 2017 - 2020 Medicgo
Powered by some medical students